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Abstract Poor and non-white patients are dispropor-
tionately infected with the hepatitis C virus (HCV). The
objective of this research is to determine sociodemographic
patterns of HCV-related ambulatory care visits over time.
Data from the National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical
Care Survey-Outpatient (NHAMCS-OPD) for the years
1997–2005 were analyzed in 3-year intervals. Demo-
graphic and other variables were compared for each period,
and multivariable logistic regression was performed to
examine whether the likelihood of a visit being HCV-
related (versus non-HCV) was independently associated
with (1) race and/or (2) Medicaid status over time. The
total number of HCV-related ambulatory visits more than
doubled from 3,583,585 during the years 1997–1999 to
8,027,166 during 2003–2005. During this time, the pro-
portion of non-whites and Medicaid recipients presenting
for HCV-related visits approximately doubled (non-whites:
16% vs. 33%, P = 0.04; Medicaid recipients: 10% vs.
25%, P = 0.07). In 2003–2005, HCV-related visits were
more than twice as likely to occur among non-white
patients vs. white patients (OR = 2.49; 95% CI: 1.60–
3.86) and patients on Medicaid vs. non-Medicaid (3.49;
1.79–6.80). Our results show that HCV-associated ambu-
latory care visits are increasing, with a greater proportion
of visits occurring among non-white patients and Medicaid
recipients.
Keywords Hepatitis C  Health disparities 
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Introduction
More than 3 million Americans are now estimated to be
infected with the hepatitis C virus (HCV) [1]. The inci-
dence of HCV peaked in the 1980s (prior to blood product
screening) and is now relatively low except among certain
high-risk groups such as injection drug users [2, 3] As a
consequence, most affected individuals are 40–50 years of
age and have likely been infected for decades. Over time,
these individuals are at risk for developing cirrhosis and
liver cancer, which has prompted concern about a potential
surge in HCV-associated morbidity and mortality in the
coming years [4]. Providing ambulatory care for HCV-
infected individuals so that they can be evaluated for
treatment should be of paramount importance.
To date, there is little information on the patterns of
ambulatory health care usage among HCV-infected per-
sons. The prevalence of HCV is disproportionately higher
among minorities, illicit drug users, and individuals of low
socioeconomic status [1]. These are vulnerable populations
that may face numerous barriers to adequate health care.
Although HCV-related healthcare utilization has been
reported to be increasing overall [5, 6], it is unclear whe-
ther these vulnerable groups are receiving care for their
HCV. This study was conducted to analyze whether the
national pattern of HCV-related ambulatory care visits
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differed by age, gender, race, and insurance status over
time, and to examine the proportion of visits that involved
a prescription for anti-HCV therapy.
Methods
Data Sources and Study Design
Data from the National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical
Care Survey-Outpatient (NHAMCS-OPD) for years 1997–
2005 were utilized. These surveys, conducted annually by
the National Center for Health Statistics and the Centers for
Disease Control, capture nationally representative samples
of visits to ambulatory clinics (NAMCS) and hospital-
based clinics (NHAMCS-OPD). A detailed description of
NAMCS and NHAMCS methodology is available through
the National Center for Health Statistics [7]. In brief,
trained interviewers provide materials and instruction to
physicians, who then record information on patient visits
during the reporting period. This study included informa-
tion only on adult visits (age 18 years or older). Because of
relatively small numbers of HCV-associated visits, we
combined annual survey data in 3-year intervals (1997–
1999, 2000–2002, and 2003–2005). Analysis of this pub-
licly available data set was exempted from institutional
review board review by the University of California, San
Francisco.
Variables
An HCV-related visit was defined as one in which any of
the three principal diagnosis fields contained the following
International Classification of Diseases, Ninth Revision
(ICD-9 codes): 070.41, 070.44, 070.51, 070.54, 070.70,
070.71, or V02.62. Demographic covariates that were
examined included age, sex, race (white vs. non-white),
and insurance status (private, Medicare, Medicaid, or
other). Additional covariates examined were whether or not
the visit was conducted with the patient’s primary care
provider (as determined by the provider), whether the visit
also contained a diagnosis code for complications from
HCV defined as cirrhosis, ascites, esophageal varices or
hepatocellular cancer (ICD-9 codes: 571.5, 571.6, 155.0,
789.5, 456.1, 456.2, or 571.2), and whether the visit
involved prescription of anti-HCV medications (standard
and pegylated interferon alpha-2a and 2b, and/or ribavirin).
Analyses
All analyses took into account the complex survey design
using weights, strata, and primary sampling unit design
variables when calculating estimates. Comparisons of the
proportion of visits representing certain patient demo-
graphics and prescription of anti-HCV therapy for each 3-
year interval were compared using a Chi-square test.
Multivariable logistic regression was performed to exam-
ine whether the likelihood of a visit being HCV-related
(versus unrelated to HCV) was independently associated
with race and Medicaid status, and whether there was an
interaction between time and those covariates (i.e., whether
the effects of race and Medicaid status varied over time). A
P-value threshold of \0.05 was used for all statistical
testing, including tests for interaction. All analyses were
conducted using SAS version 9.1.3 (SAS Institute, Cary,
NC) and SUDAAN, version 9.0.3 (RTI International,
Research Triangle Park, NC).
Results
Using this data source, it is estimated that national HCV-
related ambulatory visits increased from 3,583,585 (95%
CI: 2,305,477 to 4,861,693) during 1997–1999 to
8,027,166 (3,714,378 to 12,339,954) during 2003–2005
(Fig. 1). These weighted estimates were based on an
absolute number of 276 visits, 468 visits, and 583 visits for
the years 1997–1999, 2000–2002, and 2003–2005,
respectively (estimates are not stable for fewer than 30
visits) [7]. HCV-related visits constituted a larger per-
centage of total ambulatory visits over time: they
comprised 0.17% of total visits in 1997–1999, 0.26% in
2000–2002, and 0.33% in 2003–2005 (Chi-square P-
value = 0.04; trend P-value = 0.1).
Over the time period examined, the proportion of non-
whites and Medicaid recipients presenting for HCV-related
visits approximately doubled (Table 1). A relatively small
number of visits involved a prescription for anti-HCV
medications (\10%), and the proportion did not appear to
be changing over time. Likewise, a minority of HCV-
related visits also involved complications such as cirrhosis
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Fig. 1 Estimated number of HCV-related ambulatory visits in the
U.S.
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and liver cancer, and there was no appreciable change over
time. Almost half of all HCV-related visits occurred with
the patient’s primary care provider.
Results from the logistic regression, adjusting for age
and sex, demonstrated that HCV-related visits were more
likely to occur among non-whites and recipients of Med-
icaid over time (time–race interaction P-value = 0.02;
time–Medicaid interaction = 0.04). In the most recent
years (2003–2005), HCV-related visits were more than
twice as likely to occur among non-white patients, and
more than three times as likely to occur among patients on
Medicaid (Table 2).
Conclusions
This study suggests that the number of HCV-related
ambulatory care visits in the U.S. is rising, with an
increasing percentage of visits occurring among non-white
patients and recipients of Medicaid. Additionally, we
observed that only a small percentage (\10%) of ambula-
tory HCV-related visits involved anti-HCV treatment, and
that the proportion of visits involving treatment did not
increase between 1997 and 2005.
There are some potential explanations for our finding
that an increasing proportion of HCV-related ambulatory
visits occurred among non-whites and Medicaid recipients.
First, this may reflect the positive efforts to screen and
bring to care individuals who are infected with HCV.
National guidelines for HCV screening do not target any
particular race or socioeconomic group [8], however, the
prevalence of HCV is substantially higher among minori-
ties and individuals of low socioeconomic status.
Increasing proportions may reflect greater numbers of
individuals from these vulnerable groups who become
aware of their diagnosis and are able to access health care.
As the incidence of acute HCV is extremely low (0.3 per
Table 1 Characteristics of HCV-related ambulatory visits (NAMCS/NHAMCS-OPD combined)
1997–1999
N = 3,583,585
N (%)
2000–2002
N = 5,875,678
N (%)
2003–2005
N = 8,027,166
N (%)
P-value
Gender
Female 1,594,071 (44) 2,020,134 (34) 2,702,298 (34) 0.46
Male 1,989,514 (56) 3,855,544 (66) 5,324,868 (66)
Age
18–39 841,005 (23) 1,210,659 (21) 1,184,421 (15) 0.83
40–59 2,302,117 (64) 3,775,097 (64) 5,459,966 (68)
C60 440,463 (12) 889,922 (15) 1,382,779 (17)
Race
White 3,015,711 (84) 4,708,309 (80) 5,339,075 (67) 0.04
Non-white 567,874 (16) 1,167,369 (20) 2,688,091 (33)
Insurance
Private 2,169,151 (60) 3,029,322 (52) 3,993,254 (50) 0.21
Medicare 655,850 (18) 773,304 (13) 911,405 (11)
Medicaid 342,788 (10) 1,048,284 (18) 2,015,782 (25)
Othera 415,796 (12) 1,024,768 (17) 1,106,725 (14)
Medicaid (vs. non-Medicaid) 342,788 (10) 1,048,284 (18) 2,015,782 (25) 0.07
Diagnosis of HCV complicationsb 199,785 (6)c 314,129 (5) 508,510 (6) 0.92
Prescription of anti-HCV meds 247,138 (7)c 565,892 (9.6) 503,428 (6.3) 0.76
Primary care provider visitd 1,502,684 (45) 2,400,056 (43) 3,466,357 (45) 0.97
a Includes self-pay/charity, workers comp, other, unknown and missing
b Cirrhosis, ascites, esophageal varices or hepatocellular carcinoma
c Less than 30 visits, estimate not stable
d 105 absolute visits missing this information = 929,107 weighted visits
Table 2 Relative odds for visit being HCV-related (vs. non-HCV)
associated with race and Medicaid status*
Covariate 1997–1999 2000–2002 2003–2005
White Ref Ref Ref
Non-white 1.04 (0.58, 1.87) 1.43 (0.87, 2.34) 2.49 (1.60, 3.86)
Non-
Medicaid
Ref Ref Ref
Medicaid 1.49 (0.80, 2.80) 3.54 (2.44, 5.14) 3.49 (1.79, 6.80)
* Results from the logistic regression were adjusted for age and sex
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100,000) [3], it seems unlikely that a differential rate of
new infections among non-whites and Medicaid recipients
can fully explain our findings. Another possibility is that a
differential rate of HCV-associated complications among
whites and non-whites compels individuals to seek out
care, as some prior research has suggested disparities
between whites and blacks in liver disease outcomes [9];
however, the relatively small number of visits involving
HCV-associated complications observed appears to argue
against this being a major driving force behind our
findings.
Regardless of cause, our findings have important public
health implications. The findings support prior research
showing an increasing contribution of HCV to national
healthcare expenditures [5, 6], but add to the literature by
showing that Medicaid is increasingly shouldering the costs
of ambulatory healthcare for HCV. Politicians and policy-
makers should be aware of the potential for increased
Medicaid ambulatory care costs due to HCV. Further, if
HCV-related complications such as cirrhosis and liver
cancer (and costly treatments like liver transplant) increase
in the future, as some researchers have predicted [4], there
may be a substantial burden to the public healthcare sys-
tem. It is nonetheless interesting to note that in this study
the proportion of HCV-related ambulatory visits that were
associated with complications did not increase over the
study period. Models predicting HCV-associated burden
have projected increases in HCV-related morbidity and
mortality that peak around 2015 [10], so this study may
have been conducted too early to detect upward trends in
complications.
This study also found that only a small percentage of
HCV-related ambulatory care visits (\10%) involved pre-
scription of anti-HCV medications by the provider.
Because the data contain no patient-specific information on
treatment history, candidacy, and preferences, we cannot
determine to what extent this proportion falls short of
treatment guidelines. However, the seemingly low per-
centage of observed visits that involved treatment appears
congruent with prior research showing substantial contra-
indications and barriers to treatment for many HCV-posi-
tive patients [11, 12]. In this study, almost half of the HCV-
related visits occurred with a self-identified ‘‘primary care
provider.’’ If a significant proportion of HCV care is taking
place in the offices of non-specialist primary care provid-
ers, training non-specialist providers to treat HCV may be
one strategy to provide greater access to treatment for
patients.
This study has several important limitations. Because
the study is based on a sample of visits, rather than indi-
viduals, observations are restricted to the level of health
care utilization. There was potential for misclassification,
in particular not identifying all visits that involved HCV-
related care. Because the survey only allowed for three
diagnosis codes, patients with HCV who had multiple co-
morbidities may have not have had their visit coded to
reflect their HCV care. Finally, we had relatively small
absolute numbers of HCV-related visits and even fewer
visits that involved treatment; therefore we were unable to
examine patterns of treatment among subgroups, such as
non-whites and Medicaid recipients.
In summary, using a nationally representative survey,
we found that HCV-related ambulatory care visits are
increasing, and that more visits are occurring among non-
white and Medicaid patients over time. Since the current
incidence of HCV is low, this may reflect improved efforts
to provide care for poor, non-white individuals who are
chronically infected with HCV. Policy-makers should be
aware that HCV-related ambulatory care visits are
increasingly paid through Medicaid insurance, which may
place a growing burden on the public health care system in
the future.
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